Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years.

Rheumatol Ther · 2022 · PMC8627156 · PMID 34837630

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significanceP = 0.057so close (0.05 < p ≤ 0.1)

As a result, the difference in the primary endpoint between the secukinumab and placebo groups in MEASURE 4 did not reach statistical significance ( P = 0.057 and P = 0.054, respectively) [ 21 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.